Novartis: Strong Execution With A P/E Discount
Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...
Nasdaq6d
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis announced a definitive agreement to acquire private biotech Anthos Therapeutics, which will strengthen its cardiovascular pipeline by adding abelacimab, the latter’s lead pipeline ...
MM&M6d
Rx Rundown: Novartis, Abcuro, SpringWorks Therapeutics and more
Novartis agreed to a deal worth up to $3.1 billion for Blackstone Life Sciences’ Anthos Therapeutics. Merck KGaA confirmed that it is in talks to acquire SpringWorks Therapeutics, though a deal has ...
Is Novartis AG (NVS) the Best Foreign Dividend Stock to Buy According to Analysts?
We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...
Insider Monkey6d
13 Best Foreign Dividend Stocks To Buy According to Analysts
Novartis AG (NYSE:NVS ... On February 11, 2025, the company announced that it is buying back Anthos Therapeutics in a deal worth up to $3.1 billion, reclaiming the rights to abelacimab, a ...